Mild hyperhomocysteinemia is associated with a decreased fibrinolytic activity in patients after ST-elevation myocardial infarction

Thrombosis Research

Volumn 119, Issue 3, 2007, Pages 331-336

  Speidl, Walter Stefan ^a   Nikfardjam, Mariam ^a   Niessner, Alexander ^a   Zeiner, Andrea ^a   Jordanova, Nelli ^b   Zorn, Gerlinde ^a   Maurer, Gerald ^a   Schreiber, Wolfgang ^a   Wojta, Johann ^a   Huber, Kurt ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b WILHELMINEN HOSPITAL   (Austria)

Author keywords

Coronary artery disease; Fibrinolysis; Homocysteine; Tissue type plasminogen activator

Indexed keywords

ADULT; AGED; CORONARY ARTERY DISEASE; FEMALE; FIBRINOLYSIS; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 33845509274     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2006.02.011     Document Type: Article

References (30)

1. Mudd S.H., Skovby F., Levy H.L., Pettigrew K.D., Wilcken B., Pyeritz R.E., et al. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet 37 1 (1985) 1-31
2. Welch G.N., and Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 338 15 (1998) 1042-1050
3. Bozic M., Stegnar M., Fermo I., Ritonja A., Peternel P., Stare J., et al. Mild hyperhomocysteinemia and fibrinolytic factors in patients with history of venous thromboembolism. Thromb Res 100 4 (2000) 271-278
4. den Heijer M., Koster T., Blom H.J., Bos G.M., Briet E., Reitsma P.H., et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 334 12 (1996) 759-762
5. Seinost G., Renner W., Brodmann M., Winkler M., Koppel H., and Pilger E. C677T mutation in the methylene tetrahydrofolate reductase gene as a risk factor for venous thrombotic disease in Austrian patients. Thromb Res 100 5 (2000) 405-407
6. Nygard O., Nordrehaug J.E., Refsum H., Ueland P.M., Farstad M., and Vollset S.E. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 337 4 (1997) 230-236
7. 6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial. JAMA 288 8 (2002) 973-979
8. Schnyder G., Roffi M., Pin R., Flammer Y., Lange H., Eberli F.R., et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 345 22 (2001) 1593-1600
9. Liem A., Reynierse-Buitenwerf G.H., Zwinderman A.H., Jukema J.W., and van Veldhuisen D.J. Secondary prevention with folic acid: effects on clinical outcomes. J Am Coll Cardiol 41 12 (2003) 2105-2113
10. Bønaa K. NORVIT: randomised trial of homocysteine-lowering with B vitamins for secondary prevention of cardiovascular disease after acute myocardial infarction. Stockholm. Sept 5, 2005. European Society of Cardiology. http://www.escardio.org/knowledge/onlinelearning/slides/ESC_Congress_2005/BonaaFP1334.htm. Accessed January 30, 2006.
11. Blann A.D. Endothelial cell damage and homocysteine. Atherosclerosis 94 1 (1992) 89-91
12. Tsai J.C., Perrella M.A., Yoshizumi M., Hsieh C.M., Haber E., Schlegel R., et al. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci U S A 91 14 (1994) 6369-6373
13. Buemi M., Marino D., Di Pasquale G., Floccari F., Ruello A., Aloisi C., et al. Effects of homocysteine on proliferation, necrosis, and apoptosis of vascular smooth muscle cells in culture and influence of folic acid. Thromb Res 104 3 (2001) 207-213
14. Fryer R.H., Wilson B.D., Gubler D.B., Fitzgerald L.A., and Rodgers G.M. Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. Arterioscler Thromb 13 9 (1993) 1327-1333
15. Midorikawa S., Sanada H., Hashimoto S., and Watanabe T. Enhancement by homocysteine of plasminogen activator inhibitor-1 gene expression and secretion from vascular endothelial and smooth muscle cells. Biochem Biophys Res Commun 272 1 (2000) 182-185
16. Hajjar K.A. Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. J Clin Invest 91 6 (1993) 2873-2879
17. Kuch B., Bobak M., Fobker M., Junker R., von Eckardstein A., Marmot M., et al. Associations between homocysteine and coagulation factors-a cross-sectional study in two populations of central Europe. Thromb Res 103 4 (2001) 265-273
18. Schreiner P.J., Wu K.K., Malinow M.R., Stinson V.L., Szklo M., Nieto F.J., et al. Hyperhomocyst(e)inemia and hemostatic factors: the atherosclerosis risk in communities study. Ann Epidemiol 12 4 (2002) 228-236
19. Tofler G.H., D'Agostino R.B., Jacques P.F., Bostom A.G., Wilson P.W., Lipinska I., et al. Association between increased homocysteine levels and impaired fibrinolytic potential: potential mechanism for cardiovascular risk. Thromb Haemost 88 5 (2002) 799-804
20. Mangoni A.A., Arya R., Ford E., Asonganyi B., Sherwood R.A., Ouldred E., et al. Effects of folic acid supplementation on inflammatory and thrombogenic markers in chronic smokers. A randomised controlled trial. Thromb Res 110 1 (2003) 13-17
21. Kang S.S., Wong P.W., and Malinow M.R. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Annu Rev Nutr 12 (1992) 279-298
22. Ryan T.J., Antman E.M., Brooks N.H., Califf R.M., Hillis L.D., Hiratzka L.F., et al. 1999 update: ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction: executive summary and recommendations: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation 100 9 (1999) 1016-1030
23. Huber K., Rosc D., Resch I., Schuster E., Glogar D.H., Kaindl F., et al. Circadian fluctuations of plasminogen activator inhibitor and tissue plasminogen activator levels in plasma of patients with unstable coronary artery disease and acute myocardial infarction. Thromb Haemost 60 3 (1988) 372-376
24. Carroll V.A., Griffiths M.R., Geiger M., Merlo C., Furlan M., Lammle B., et al. Plasma protein C inhibitor is elevated in survivors of myocardial infarction. Arterioscler Thromb Vasc Biol 17 1 (1997) 114-118
25. Wojta J., Holzer M., Hufnagl P., Christ G., Hoover R.L., and Binder B.R. Hyperthermia stimulates plasminogen activator inhibitor type 1 expression in human umbilical vein endothelial cells in vitro. Am J Pathol 139 4 (1991) 911-919
26. Geppert A., Graf S., Beckmann R., Hornykewycz S., Schuster E., Binder B.R., et al. Concentration of endogenous tPA antigen in coronary artery disease: relation to thrombotic events, aspirin treatment, hyperlipidemia, and multivessel disease. Arterioscler Thromb Vasc Biol 18 10 (1998) 1634-1642
27. Wiesbauer F., Kaun C., Zorn G., Maurer G., Huber K., and Wojta J. HMG CoA reductase inhibitors affect the fibrinolytic system of human vascular cells in vitro: a comparative study using different statins. Br J Pharmacol 135 1 (2002) 284-292
28. Andersen P., Seljeflot I., Herzog A., Arnesen H., Hjermann I., and Holme I. Effects of doxazosin and atenolol on atherothrombogenic risk profile in hypertensive middle-aged men. J Cardiovasc Pharmacol 31 5 (1998) 677-683
29. Hultdin J., Thogersen A.M., Jansson J.H., Nilsson T.K., Weinehall L., and Hallmans G. Elevated plasma homocysteine: cause or consequence of myocardial infarction?. J Intern Med 256 6 (2004) 491-499
30. Goto S., Kawai Y., Handa S., Abe S., Takahashi E., Watanabe K., et al. Serial changes in plasma concentration of plasminogen activator inhibitor-1 before and serially after thrombolytic therapy for acute myocardial infarction. Cardiology 82 4 (1993) 280-285